Stellenwert der B-Zell-gerichteten Therapie bei Granulomatose mit Polyangiitis und Mikroskopischer Polyangiitis

Schlüsselwörter

Granulomatose mit Polyangiitis - Mikroskopische Polyangiitis - Therapie - B-Zell-gerichtete Therapie - Rituximab

Keywords

granulomatosis with polyangiitis - microscopic polyangiitis - therapy - B-cell-targeted therapy - rituximab

• Literatur

• 1 Cartin-Ceba R, Fervenza FC, Specks U. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol 2012; 24: 15-23
• 2 Cartin-Ceba R, Golbin JM, Koegh KA et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten year experience at a single center. Arthritis Rheum 2012; 64: 3770-3778
• 3 Charles P, Bienvenu B, Bonnotte B et al. Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013; 42: 1317-1330
• 4 de Groot K. Renal disease in small-vessel vasculitis. Cleve Clin J Med 2012; 79 (Suppl. 03) S22-26
• 5 Fachinformation MabThera. Stand Juni 2013
• 6 Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 100-105
• 7 Fleck M, Hellmich B. Vasculitis. Dtsch Med Wochenschr 2013; 138: 1236-1239
• 8 Gibelin A, Maldinie C, Mahr A. Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med 2011; 32: 264-273
• 9 Gómez-Puerta JA, Quintana LF, Stone JH et al. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev 2012; 11: 646-652
• 10 Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Arthritis Rheum 2012; S706: 1652
• 11 Haubitz M. Rituximab bei Vaskulitiden. Nephrologe 2012; 7: 227-232
• 12 Hellmich B, Pflugfelder J. ANCA-assoziierte Vaskulitiden. Akt Rheumatol 2013;
• 13 Hinze CH, Colbert RA. B-cell depletion in Wegener's granulomatosis. Clinic Rev Allerg Immunol 2008; 34: 372-379
• 14 Holle JU. ANCA („anti-neutrophil cytoplasm antibody“)-assoziierte Vaskulitiden. CME zertifizierte Fortbildung. Z Rheumatol 2013; 72: 445-456
• 15 http://clinicaltrials.gov/ct2/show/NCT01731561?term=MAINRITSAN+2&rank=1 (Zugriff 17.1.2014)
• 16 http://www.vasculitis.org/images/pexivas%201.1%20protocol.pdf (Zugriff 17.1.2014)
• 17 Jayne DR, Gaskin G, Rasmussen N et al. for the European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vascultis. J Am Soc Nephrol 2007; 18: 2180-2188
• 18 Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
• 19 Jones RB, Cohen Tervaert JW, Hauser T et al. Two year follow-up results from a randomised trial of rituximab versus cyclophosphamide for generalized ANCA-associated vasculitis: RITUXVAS. Arthritis Rheum 2010; 62 (10) (Suppl. 01) S282: Abstr. 676
• 20 Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
• 21 Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168
• 22 KDIGO. Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplements 2012; 2: 259-274
• 23 Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100: 82-85
• 24 Lapraik C, Watts R, Bacon P et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 2007; 46: 1-11
• 25 Le Guenno G, Mahr A, Pagnoux C et al. French Vasculitis Study Group. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63: 1435-1445
• 26 Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
• 27 Neumann T, Wolf G. Nierenbeteiligung bei systemischen Vaskulitiden. Akt Rheumatol 2011; 36: 297-306
• 28 Puisset F, White-Koning M, Kamar N et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 2013; 76: 734-740
• 29 Smith RM, Jones RB, Guerry MJ et al. Rituximab for maintenance of remission in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3760-3769
• 30 Specks U, Merkel PA, Seo P et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-427
• 31 Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
• 32 Terrier B, Pagnoux C, Karras A et al. Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow up at 39 months (abstract). Arthritis Rheum 2013; 65 (Suppl. 10) 2783
• 33 van Vollenhoven RF, Emery P, Bingham CO et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496-1502
• 34 Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-548
• 35 Walsh M, Casian A, Flossmann O. European Vasculitis Study Group (EUVAS) et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402